NO2794666T3 - - Google Patents

Info

Publication number
NO2794666T3
NO2794666T3 NO12859384A NO12859384A NO2794666T3 NO 2794666 T3 NO2794666 T3 NO 2794666T3 NO 12859384 A NO12859384 A NO 12859384A NO 12859384 A NO12859384 A NO 12859384A NO 2794666 T3 NO2794666 T3 NO 2794666T3
Authority
NO
Norway
Application number
NO12859384A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2794666T3 publication Critical patent/NO2794666T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO12859384A 2011-12-19 2012-12-19 NO2794666T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2011/051538 WO2013095215A1 (en) 2011-12-19 2011-12-19 Low anticoagulant heparins
PCT/SE2012/051429 WO2013095277A1 (en) 2011-12-19 2012-12-19 Use of chemically modified heparin derivates in sickle cell disease

Publications (1)

Publication Number Publication Date
NO2794666T3 true NO2794666T3 (cg-RX-API-DMAC10.html) 2018-07-21

Family

ID=48668926

Family Applications (2)

Application Number Title Priority Date Filing Date
NO12860938A NO2794667T3 (cg-RX-API-DMAC10.html) 2011-12-19 2012-12-19
NO12859384A NO2794666T3 (cg-RX-API-DMAC10.html) 2011-12-19 2012-12-19

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO12860938A NO2794667T3 (cg-RX-API-DMAC10.html) 2011-12-19 2012-12-19

Country Status (26)

Country Link
US (2) US9480701B2 (cg-RX-API-DMAC10.html)
EP (2) EP2794666B1 (cg-RX-API-DMAC10.html)
JP (2) JP6703806B2 (cg-RX-API-DMAC10.html)
CN (1) CN104053675B (cg-RX-API-DMAC10.html)
AU (1) AU2012354226B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014014673B1 (cg-RX-API-DMAC10.html)
CA (2) CA2856918C (cg-RX-API-DMAC10.html)
CY (2) CY1120194T1 (cg-RX-API-DMAC10.html)
DK (2) DK2794667T3 (cg-RX-API-DMAC10.html)
ES (2) ES2668273T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20180725T1 (cg-RX-API-DMAC10.html)
HU (2) HUE037555T2 (cg-RX-API-DMAC10.html)
IL (1) IL232903A (cg-RX-API-DMAC10.html)
IN (1) IN2014MN01056A (cg-RX-API-DMAC10.html)
MX (1) MX358439B (cg-RX-API-DMAC10.html)
MY (1) MY170069A (cg-RX-API-DMAC10.html)
NO (2) NO2794667T3 (cg-RX-API-DMAC10.html)
PH (1) PH12014501387B1 (cg-RX-API-DMAC10.html)
PL (2) PL2794667T3 (cg-RX-API-DMAC10.html)
PT (2) PT2794667T (cg-RX-API-DMAC10.html)
RS (2) RS57214B1 (cg-RX-API-DMAC10.html)
SI (2) SI2794666T1 (cg-RX-API-DMAC10.html)
SM (2) SMT201800217T1 (cg-RX-API-DMAC10.html)
TN (2) TN2014000236A1 (cg-RX-API-DMAC10.html)
WO (3) WO2013095215A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201403654B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
DK2794665T3 (da) 2011-12-19 2018-01-29 Dilafor Ab Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
EP2965764A1 (en) * 2014-07-11 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
EP3137099B1 (en) * 2014-04-30 2019-09-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Dnase for use in treating vaso-occlusive crisis
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
EP3773770B1 (en) * 2018-04-13 2023-11-29 University of Virginia Patent Foundation Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels
CN109481692A (zh) * 2018-11-30 2019-03-19 东南大学 一种青蒿琥酯肝素衍生物及其药物组合物和应用
WO2023192343A1 (en) * 2022-03-29 2023-10-05 The Penn State Research Foundation Bioactive granular hydrogel scaffolds and use thereof
US12444880B2 (en) 2022-05-05 2025-10-14 Tego Innovations, Inc. Magnetic power distribution assembly
WO2023239719A1 (en) 2022-06-06 2023-12-14 Ihp Therapeutics Inc. Chemically modified heparin
EP4536248A4 (en) * 2022-06-06 2026-02-11 Ihp Therapeutics Inc CHEMICALLY MODIFIED HEPARIN
CN115448994B (zh) * 2022-09-28 2023-08-01 山东大学 一种可中和抗凝低分子量肝素及其制备方法和应用
AU2023352919A1 (en) 2022-09-29 2025-03-13 Adora Life Science, Inc. Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
GB2625581A (en) * 2022-12-21 2024-06-26 Modus Therapeutics Ab New medical use
WO2024170746A1 (en) 2023-02-17 2024-08-22 Modus Therapeutics Ab New medical use of sevuparin in the treatment of endotoxemia
GB2627263A (en) * 2023-02-17 2024-08-21 Modus Therapeutics Ab New medical use
CN116854838A (zh) * 2023-06-30 2023-10-10 重庆望业药物研究有限公司 低分子多糖及其制备方法与应用
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
ES2054975T3 (es) * 1988-10-07 1994-08-16 Hoechst Ag Composiciones antimalaricas que emplean quinidina, artemisinina y sus derivados.
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) * 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
WO1994008595A1 (en) 1992-10-13 1994-04-28 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
DE69623840D1 (de) * 1995-03-31 2002-10-31 Hamilton Civic Hospitals Res Zusammensetzung zur Hemmung der Thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
NZ330603A (en) 1996-10-15 2000-01-28 Toray Industries Hyaluronic acid derivatives used as cervical ripening agents
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
CA2310422A1 (en) * 1997-11-20 1999-06-03 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
US6596705B1 (en) * 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
WO1999043714A1 (fr) 1998-02-26 1999-09-02 Seikagaku Corporation Nouveaux derives de polysaccharide, leur procede de production, et compositions medicinales contenant ces nouveaux derives comme principe actif
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
WO2000006608A1 (en) * 1998-07-31 2000-02-10 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
HK1045532A1 (zh) * 1999-06-30 2002-11-29 Hamilton Civic Hospitals Research Development, Inc. 抑制与凝结有关凝结因子的肝素成份
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
WO2002023190A2 (en) * 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
AU2003230985A1 (en) 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1582531A1 (en) * 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US8383154B2 (en) * 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
BRPI0613677A2 (pt) 2005-07-22 2011-01-25 Trf Pharma Inc método para tratar doença de célula falsiforme e sequelas da doença de célula falsiforme
US20070021378A1 (en) * 2005-07-22 2007-01-25 The Regents Of The University Of California Heparin compositions and selectin inhibition
AU2007267561B2 (en) * 2006-05-25 2012-05-17 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (en) * 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8445436B2 (en) 2007-12-03 2013-05-21 Florida State University Research Foundation, Inc. Oxytocin and melatonin compositions and associated methods for inducing labor
JP5758797B2 (ja) * 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
WO2010009492A1 (en) * 2008-07-25 2010-01-28 Alphapharm Pty Ltd ATOVAQUONE WITH A PARTICLE SIZE DIAMETER RANGE (D90) OF GREATER THAN 3 μM TO ABOUT 10 μM
DK2419736T3 (da) 2009-04-16 2014-04-22 Momenta Pharmaceuticals Inc Fremgangsmåder til vurdering af aktivitet af en polysaccharidsammensætning
WO2011000032A1 (en) * 2009-06-30 2011-01-06 Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
DK2794665T3 (da) 2011-12-19 2018-01-29 Dilafor Ab Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104203256B (zh) 2012-03-26 2017-11-24 迪乐方有限责任公司 用于引产的包含硫酸化的葡糖胺聚糖的联合治疗
NZ631279A (en) 2012-03-26 2016-06-24 Dilafor Ab Method for treatment of labor arrest

Also Published As

Publication number Publication date
MX2014006956A (es) 2014-10-17
EP2794667A1 (en) 2014-10-29
US20150031638A1 (en) 2015-01-29
US9480702B2 (en) 2016-11-01
PT2794667T (pt) 2018-05-16
JP2015500387A (ja) 2015-01-05
SI2794667T1 (en) 2018-06-29
ZA201403654B (en) 2017-08-30
CN104053675A (zh) 2014-09-17
CA2856918C (en) 2017-07-04
WO2013095277A1 (en) 2013-06-27
SMT201800217T1 (it) 2018-05-02
CN104053675B (zh) 2016-10-12
JP2018154848A (ja) 2018-10-04
SI2794666T1 (en) 2018-06-29
MX358439B (es) 2018-08-21
HRP20180726T1 (hr) 2018-06-15
CA2856918A1 (en) 2013-06-27
EP2794666A4 (en) 2015-07-22
AU2012354226A1 (en) 2014-06-05
IN2014MN01056A (cg-RX-API-DMAC10.html) 2015-05-01
MY170069A (en) 2019-07-03
BR112014014673B1 (pt) 2021-02-17
US20140364369A1 (en) 2014-12-11
HRP20180725T1 (hr) 2018-06-29
JP6703806B2 (ja) 2020-06-03
NZ625096A (en) 2016-07-29
HK1200471A1 (en) 2015-08-07
CY1120194T1 (el) 2018-12-12
EP2794667A4 (en) 2015-07-22
TN2014000237A1 (en) 2015-09-30
WO2013095215A1 (en) 2013-06-27
PL2794667T3 (pl) 2018-09-28
CA2856477C (en) 2017-06-27
US9480701B2 (en) 2016-11-01
SMT201800218T1 (it) 2018-05-02
IL232903A (en) 2017-02-28
CY1120197T1 (el) 2018-12-12
TN2014000236A1 (en) 2015-09-30
EP2794666B1 (en) 2018-02-21
IL232903A0 (en) 2014-07-31
HUE037554T2 (hu) 2018-09-28
AU2012354226B2 (en) 2017-01-12
ES2669055T3 (es) 2018-05-23
CA2856477A1 (en) 2013-06-27
RS57213B1 (sr) 2018-07-31
EP2794666A1 (en) 2014-10-29
NO2794667T3 (cg-RX-API-DMAC10.html) 2018-07-21
EP2794667B1 (en) 2018-02-21
PL2794666T3 (pl) 2018-08-31
WO2013095276A1 (en) 2013-06-27
BR112014014673A2 (pt) 2017-06-13
PT2794666T (pt) 2018-05-09
ES2668273T3 (es) 2018-05-17
DK2794666T3 (en) 2018-04-23
BR112014014673A8 (pt) 2017-07-04
PH12014501387A1 (en) 2014-09-22
HK1199893A1 (en) 2015-07-24
DK2794667T3 (en) 2018-04-23
PH12014501387B1 (en) 2014-09-22
RS57214B1 (sr) 2018-07-31
HUE037555T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
BR112013022641A2 (cg-RX-API-DMAC10.html)
BR112013031251A2 (cg-RX-API-DMAC10.html)
BR112013027245A2 (cg-RX-API-DMAC10.html)
BR112013024383A2 (cg-RX-API-DMAC10.html)
BR112013023185A2 (cg-RX-API-DMAC10.html)
BR112013022995A2 (cg-RX-API-DMAC10.html)
BR112013017670A2 (cg-RX-API-DMAC10.html)
BR112013027830A2 (cg-RX-API-DMAC10.html)
AP3853A (cg-RX-API-DMAC10.html)
BR112013023927A2 (cg-RX-API-DMAC10.html)
BR112013027452A2 (cg-RX-API-DMAC10.html)
BR112013024365A2 (cg-RX-API-DMAC10.html)
BR112013028733A2 (cg-RX-API-DMAC10.html)
BR112013027121A2 (cg-RX-API-DMAC10.html)
AP2016009466A0 (cg-RX-API-DMAC10.html)
BR112013026790A2 (cg-RX-API-DMAC10.html)
BR112013024588A2 (cg-RX-API-DMAC10.html)
BR112013031556A2 (cg-RX-API-DMAC10.html)
BR112013032368A2 (cg-RX-API-DMAC10.html)
BR112013018949A2 (cg-RX-API-DMAC10.html)
BR112013032377A2 (cg-RX-API-DMAC10.html)
NO2794667T3 (cg-RX-API-DMAC10.html)
BR112013027761A2 (cg-RX-API-DMAC10.html)
BR112013021637A2 (cg-RX-API-DMAC10.html)
BR112013025487A2 (cg-RX-API-DMAC10.html)